EXMER

Main information

Trade name:
EXMER VIAL VIAL

Active ingredient:
MEROPENEM

Available from:
EXCELLA

Dosage:
500MG

Pharmaceutical form:
VIAL

Composition:
VIAL

Medicine domain:
Humans

Medicine type:
Allopathic drug

Documents

for the general public:
The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for the general public.

for healthcare professionals:
The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for healthcare professionals.

Localization

Available in:
India

Language:
English

Other information

Status

Source:
Central Drugs Standard Control Organization

Last update:
09-08-2016

The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for the general public.

Access to this document is only available to registered users.

Register now for full access

21-9-2018

Pending EC decision: Vabomere, meropenem / vaborbactam, Opinion date: 20-Sep-2018

Europe - EMA - European Medicines Agency

18-12-2018

Human medicines European public assessment report (EPAR): Vabomere, meropenem / vaborbactam, Urinary Tract Infections,Bacteremia,Bacterial Infections,Respiratory Tract Infections,Pneumonia,Pneumonia, Ventilator-Associated, Date of authorisation: 20/11/20

Human medicines European public assessment report (EPAR): Vabomere, meropenem / vaborbactam, Urinary Tract Infections,Bacteremia,Bacterial Infections,Respiratory Tract Infections,Pneumonia,Pneumonia, Ventilator-Associated, Date of authorisation: 20/11/2018, Status: Authorised

Europe - EMA - European Medicines Agency

22-11-2018

Vabomere (Rempex London Limited)

Vabomere (Active substance: meropenem/vaborbactam) - Centralised - Authorisation - Commission Decision (2018)7888 of Thu, 22 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4669/00

Europe -DG Health and Food Safety